Anavex Life Sciences Corp (AVXL)

[polarbear77]

On 6/25/19 the first Rett patient was announced in the Anavex 2-73 open label Rett Syndrome extension study.

“The open label, 12 week extension study is designed to evaluate long term safety, tolerability, and the effect of ANAVEX®2-73 on Rett syndrome patients following the completion of the Phase 2 study.”

So almost 4 months of open label Rett data & results for Anavex to study thus far.

As the extension is uncontrolled, they can evaluate the extension patients’ progress and liquid dosage titrations and effects throughout.

Correlations with the established biomarkers and increases in dosages.

Data is continuing to pile up in this extension and my opinion is that it is continuing to confirm our 7 week preliminary significantly positive efficacy & behavior results.

Why? Because while only the Company has that open label extension data at this point, IMO said extension data must be pointing to similar positive biomarker-correlated efficacy and behavior improvements, logically-speaking; otherwise I think that Dr M and Dr K would have had serious reservations about presenting and putting out 3 p/r’s announcing these significant improvements in the preliminary 7 week Rett Syndrome trial (6 out of 6) positive participant results in September.

Just my opinion & intuition.

https://www.anavex.com/anavex-life-sciences-announces-first-patient-dosed-in-extension-study-to-its-u-s-phase-2-clinical-trial-of-anavex2-73-in-patients-for-rett-syndrome/